Its primary mode of action involves binding to a receptor in the body called epidermal growth factor receptor (EGFR). As a result, Erbitux blocks certain proteins from binding to EGFR, which slows down the growth of cancer cells. This medication does not cure cancer, however.
(Click Erbitux to learn more about the mode of action for this drug, possible side effects, dosing guidelines, and more.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click